Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01672853 · ClinicalTrials.gov registry record · Phase 2
Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 235
- Enrollment target
NCT01672853: Completed Phase 2 study, sponsored by Gilead Sciences.
NCT01672853 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 235 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01672853, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 235 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether simtuzumab (GS-6624) is effective at preventing the progression of liver fibrosis in adults with primary sclerosing cholangitis (PSC).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Simtuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2013-03-04 |
| Est. Completion | 2016-08-24 |
| Phase | Phase 2 |
What the finished NCT01672853 record still lists
NCT01672853 is an interventional study that assigns participants to a tested intervention. The registered 235 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01672853 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01672853 about?
NCT01672853 is a clinical study titled "Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)". The purpose of this study is to evaluate whether simtuzumab (GS-6624) is effective at preventing the progression of liver fibrosis in adults with primary sclerosing cholangitis (PSC).
What is the current status of trial NCT01672853?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 235 participants. The study started on 2013-03-04. Estimated completion is 2016-08-24.
What interventions are being tested in trial NCT01672853?
The interventions under investigation include: Placebo (BIOLOGICAL), Simtuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01672853?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01672853's enrollment target sits among peer trials
235 255th of 2000 higher than 1,746 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01524211 · 235 participants · NA
Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms
- NCT05316155 · 235 participants · Phase 1
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
- NCT05353569 · 235 participants · NA
Coherent Optical Detection of Middle Ear Disease
- NCT05390918 · 235 participants · NA
Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI